EUCTR2010-023086-21-DE进行中（未招募）不适用
An open-label, multicentre study to evaluate the immunogenicity and safety of one dose of a diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (REPEVAX®) followed by 2 doses of a diphtheria, tetanus and poliomyelitis vaccine (REVAXIS®) in subjects of 40 years of age or older without a previous diphtheria and tetanus-containing booster within the last 20 years
Sanofi Pasteur MSD S.N.C.0 个研究点目标入组 335 人开始时间: 2010年10月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 335
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects have to meet all the following criteria to be eligible for inclusion:
- •1. Adults aged =40 years at Visit 1
- •2. No receipt of a booster dose with a tetanus-, diphtheria-containing vaccine within the last 20 years before Visit 1
- •3. Having signed the informed consent form before any specific study procedure
- •4. Subject able to attend all scheduled visits and to comply with all study procedures
- •5. For France only: subject affiliated to a health social security system
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects must not be included in the study if they meet at least one of the following criteria:
- •1. Medically diagnosed pertussis disease within the last 10 years prior to Visit 1
- •2. Receipt of any inactivated vaccine within 14 days prior to Visit 1, or planned vaccination, other than study vaccines, 14 days before or after each study vaccination or study blood sample
- •3. Receipt of any live vaccine within 28 days prior to Visit 1, or planned vaccination, other than study vaccines, 28 days before or after each study vaccination or study blood sample
- •4. Febrile illness (body temperature =38.0°C) or moderate or severe acute illness/infection on the day of each vaccination, according to investigator judgment (in that case, vaccination could be postponed)
- •5. Known pregnancy or positive urine pregnancy test for women of child-bearing age. A woman who is of reproductive potential must agree to remain abstinent or use (or have her partner use) acceptable methods of birth control during the study period
- •6. History of hypersensitivity or anaphylactic or other allergic reactions to formaldehyde, glutaraldehyde, neomycin, polymyxin B and streptomycin, or to any of the vaccine components, or history of a life-threatening reaction to the study vaccines or a vaccine containing any of the same substances
- •7. History of Guillain Barré syndrome or brachial neuritis following a previous vaccination
- •8. History of encephalopathy of unknown origin within 7 days after immunization with a pertussis-containing vaccine or neurological disorders after an injection with the same antigens
- •9. Known or suspected immune dysfunction that is caused by a medical condition, or any other cause
- •- Examples: immune dysfunction including congenital immunodeficiency, human immunodeficiency virus (HIV) infection, organ or bone marrow transplantation, acute or chronic leukaemias, lymphoma, Hodgkin’s disease, multiple myeloma, other conditions affecting the bone marrow or the lymphatic system or generalized malignancy
- •- Exceptions: subjects with prostate or breast cancer with no chemotherapeutic drugs or receiving only hormone blocking drugs, subjects with skin cancer who are not receiving radiation therapy or chemotherapy, and subjects with a history of other malignancies who have been disease-free for at least 6 months can be included
- •10. Receipt of immunosuppressive therapy or expected to receive immunosuppressive therapy during the study e.g.:
- •- Chemotherapy agents to treat cancer received within 6 months prior to Visit 1 or planned treatment with chemotherapy agents during the study
- •- Daily -or on alternate days- systemic corticosteroids at a dose =20 mg/day of prednisone (or equivalent) for =14 days in the 4 weeks prior or after each vaccination
- •- Immunomodulator therapy within 6 weeks prior or after each vaccination
- •11. Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks prior to Visit 1 contraindicating intramuscular vaccination
- •12. Receipt of immunoglobulins or any blood products, other than autologous blood transfusion, given within the 5 months prior to Visit 1 or planned treatment with immunoglobulins or blood products during the study
- •13. Chronic disease (e.g., cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric) that is unstable or any intercurrent illness that might interfere with the ability to participate fully in the study; or interfere with evaluation of the vaccine
- •14. Subject deprived of freedom by an administra
研究者
相似试验
进行中（未招募）
不适用
An open-label, multi-center study to evaluate the efficacy of nilotinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and sunitinibEUCTR2008-000357-35-GBovartis Pharma GmbH
进行中（未招募）
不适用
An open-label, multi-center study to evaluate the efficacy of nilotinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and sunitinib - NDEUCTR2008-000357-35-ITOVARTIS FARMA206
进行中（未招募）
不适用
An open-label, multi-center study to evaluate the efficacy of nilotinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and sunitinibEUCTR2008-000357-35-DEovartis Pharma GmbH
进行中（未招募）
不适用
An open-label, multicenter, study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of three dosing regimens of oral AT2220 in patients with Pompe diseasePompe DiseaseEUCTR2008-002302-18-DEAmicus Therapeutics, Inc.18
进行中（未招募）
不适用
An open-label, multicenter, study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of three dosing regimens of oral AT2220 in patients with Pompe diseaseMedDRA version: 9.1Level: LLTClassification code 10036143Term: Pompe's diseasePompe DiseaseEUCTR2008-002302-18-GBAmicus Therapeutics, Inc.18